These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25972301)

  • 1. The ratio of the neutrophil leucocytes to the lymphocytes predicts the outcome after cardiac resynchronization therapy.
    Boros AM; Széplaki G; Perge P; Jenei Z; Bagyura Z; Zima E; Molnár L; Apor A; Becker D; Gellér L; Prohászka Z; Merkely B
    Europace; 2016 May; 18(5):747-54. PubMed ID: 25972301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement C3a predicts outcome in cardiac resynchronization therapy of heart failure.
    Széplaki G; Boros AM; Szilágyi S; Osztheimer I; Jenei Z; Kosztin A; Nagy KV; Karády J; Molnár L; Tahin T; Zima E; Gellér L; Prohászka Z; Merkely B
    Inflamm Res; 2016 Dec; 65(12):933-940. PubMed ID: 27492980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of the Red Blood Cell Distribution Width Improves the Risk Prediction in Cardiac Resynchronization Therapy.
    Boros AM; Perge P; Jenei Z; Karády J; Zima E; Molnár L; Becker D; Gellér L; Prohászka Z; Merkely B; Széplaki G
    Dis Markers; 2016; 2016():7304538. PubMed ID: 26903690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperuricemia predicts adverse clinical outcomes after cardiac resynchronization therapy.
    Perge P; Boros AM; Zima E; Gellér L; Merkely B; Széplaki G
    Scand Cardiovasc J; 2018 Oct; 52(5):250-255. PubMed ID: 30714413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longer right to left ventricular activation delay at cardiac resynchronization therapy implantation is associated with improved clinical outcome in left bundle branch block patients.
    Kosztin A; Kutyifa V; Nagy VK; Geller L; Zima E; Molnar L; Szilagyi S; Ozcan EE; Szeplaki G; Merkely B
    Europace; 2016 Apr; 18(4):550-9. PubMed ID: 26116830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy.
    Arrigo M; Truong QA; Szymonifka J; Rivas-Lasarte M; Tolppanen H; Sadoune M; Gayat E; Cohen-Solal A; Ruschitzka F; Januzzi JL; Singh JP; Mebazaa A
    Europace; 2017 Nov; 19(11):1848-1854. PubMed ID: 28096288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of serum NT-ProBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure.
    Yu CM; Fung JW; Zhang Q; Chan CK; Chan I; Chan YS; Kong SL; Sanderson JE; Lam CW
    J Card Fail; 2005 Jun; 11(5 Suppl):S42-6. PubMed ID: 15948100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population.
    Sokal A; Lenarczyk R; Kowalski O; Mitrega K; Pluta S; Stabryla-Deska J; Streb W; Urbanik Z; Krzeminski TF; Kalarus Z
    Heart Rhythm; 2016 May; 13(5):1088-1095. PubMed ID: 26776557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic importance of natriuretic peptides and atrial fibrillation in patients receiving cardiac resynchronization therapy.
    Smit MD; Maass AH; Hillege HL; Wiesfeld AC; Van Veldhuisen DJ; Van Gelder IC
    Eur J Heart Fail; 2011 May; 13(5):543-50. PubMed ID: 21330294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy.
    van Diepen S; Newby LK; Lopes RD; Stebbins A; Hasselblad V; James S; Roe MT; Ezekowitz JA; Moliterno DJ; Neumann FJ; Reist C; Mahaffey KW; Hochman JS; Hamm CW; Armstrong PW; Granger CB; Theroux P;
    Int J Cardiol; 2013 Oct; 168(3):2127-33. PubMed ID: 23394896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of ventricular resynchronization reserve by radionuclide phase analysis in heart failure patients: a prospective long-term study.
    Dauphin R; Nonin E; Bontemps L; Vincent M; Pinel A; Bonijoly S; Barborier D; Ribier A; Fernandes CM; Bert-Marcaz P; Itti R; Chevalier P
    Circ Cardiovasc Imaging; 2011 Mar; 4(2):114-21. PubMed ID: 21239562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department.
    Bahrmann P; Bahrmann A; Hofner B; Christ M; Achenbach S; Sieber CC; Bertsch T
    Eur Heart J Acute Cardiovasc Care; 2015 Apr; 4(2):137-47. PubMed ID: 25002708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
    de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
    Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score.
    Scrutinio D; Ammirati E; Guida P; Passantino A; Raimondo R; Guida V; Sarzi Braga S; Pedretti RF; Lagioia R; Frigerio M; Catanzaro R; Oliva F
    Int J Cardiol; 2013 Oct; 168(3):2120-6. PubMed ID: 23395457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, echocardiographic, and neurohormonal response to cardiac resynchronization therapy: are they interchangeable?
    Hoogslag GE; Höke U; Thijssen J; Auger D; Marsan NA; Wolterbeek R; Holman ER; Schalij MJ; Bax JJ; Verwey HF; Delgado V
    Pacing Clin Electrophysiol; 2013 Nov; 36(11):1391-401. PubMed ID: 23826659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study.
    Berger R; Shankar A; Fruhwald F; Fahrleitner-Pammer A; Freemantle N; Tavazzi L; Cleland JG; Pacher R
    Eur Heart J; 2009 Sep; 30(17):2109-16. PubMed ID: 19493864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure mortality according to acute variations in N-terminal pro B-type natriuretic peptide and cystatin C levels.
    Carrasco-Sánchez FJ; Pérez-Calvo JI; Morales-Rull JL; Galisteo-Almeda L; Páez-Rubio I; Barón-Franco B; Aguayo-Canela M; Pujol-De la llave E
    J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):115-21. PubMed ID: 24522084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiorenal status using amino-terminal pro-brain natriuretic peptide and cystatin C on cardiac resynchronization therapy outcomes: From the BIOCRT Study.
    Truong QA; Szymonifka J; Januzzi JL; Contractor JH; Deaño RC; Chatterjee NA; Singh JP
    Heart Rhythm; 2019 Jun; 16(6):928-935. PubMed ID: 30590191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.
    Cleland J; Freemantle N; Ghio S; Fruhwald F; Shankar A; Marijanowski M; Verboven Y; Tavazzi L
    J Am Coll Cardiol; 2008 Aug; 52(6):438-45. PubMed ID: 18672164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of N-terminal pro-brain natriuretic peptide and C-reactive protein to predict ICU mortality in unselected medical ICU patients: a prospective, observational study.
    Wang F; Pan W; Pan S; Wang S; Ge Q; Ge J
    Crit Care; 2011; 15(1):R42. PubMed ID: 21272380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.